Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006-2020.

There is significant racial disparity in prostate cancer (PCa) in terms of incidence, treatment, and outcomes. Racial diversity and compliance with FDA race reporting guidelines in PCa drug registration trials are unknown.